Drugs / [18F]P17-059
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03903549 | Jul → Dec 2022 | Parkinson disease | Five Eleven Pharma, Inc. | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [18F]P17-059 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03903549 ↗ |